About Bastiaan Kluft

This author has not yet filled in any details.
So far Bastiaan Kluft has created 7 blog entries.

Dr Martin Bakker joins SeraNovo

By |2019-02-06T17:08:07+00:00January, 2019|

Experienced business developer Martin Bakker has joined SeraNovo effective immediately. Following substantial recent progress, we have added Martin to our business development team. Martin has a proven track record within the formulation industry and is enthusiast about joining our team and expanding our commercial reach.

SeraNovo wins Venture Challenge 2018

By |2019-02-06T17:13:36+00:00November, 2018|

Chrétien Herben, director of the LifeSciences@Work Accelerator, announced SeraNovo as winning team of the 20th edition of the Venture Challenge. The Leiden-based start-up SeraNovo helps pharmaceutical companies increase bioavailability of their drugs through an innovative formulation platform.

According to the Venture Challenge jury, the platform addresses a great need of the pharmaceutical industry. SeraNovo has impressed the jury with their expertise and presentation skills at the Venture Challenge finals at Loyens & Loeff last week.

Patent Filed

By |2019-02-06T17:12:15+00:00November, 2018|

We have further added to our intellectual property portfolio. In the pharmaceutical industry protecting your breakthrough technology is very important. With this filing SeraNovo have added significant protection to the Eutech platform broadening its capabilities substantially. For this piece of IP SeraNovo have successfully collaborated with Harrie Marsman of V.O. patent attorneys.

In Vivo Proof of Concept

By |2019-02-06T17:14:30+00:00October, 2018|

SeraNovo achieved excellent in vivo results improving the bioavailability of itraconazole by more than 230% compared to the best commercial formulation. Itraconazole is a notorious drug molecule because it is so poorly soluble and subsequently poorly bioavailable. To prove our technology, we designed a new itraconazole formulation. After excellent in vitro results, we commissioned a CRO to complete a comparative in vivo study between our formulation and the best commercial formulation. This evidence of efficacy has generated significant commercial interest.

Prof. Dr. Erik Frijlink joins SeraNovo

By |2019-02-06T17:15:42+00:00July, 2018|

Dr Erik Frijlink is a Professor of Pharmaceutical Technology and Biopharmacy at University of Groningen as well as a successful pharmaceutical inventor. With widely recognized expertise in the formulation of poorly soluble small molecules Erik is an excellent addition to the SeraNovo advisory board. Erik’s technical knowledge in formulation science and industry experience will be incredible valuable as we continue to enhance our platform.